Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities

Gynecologic malignancies, mainly including ovarian cancer, cervical cancer and endometrial cancer, are leading causes of death among women worldwide with high incidence and mortality rate. Recently, adoptive T cell therapy (ACT) using engineered T cells redirected by genes which encode for tumor-spe...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yifan, Jiang, Jin, Wang, Yutong, Wang, Wei, Li, Haokun, Lai, Wenyu, Zhou, Zhipeng, Zhu, Wei, Xiang, Zheng, Wang, Zhiming, Zhu, Zhe, Yu, Lingfeng, Huang, Xiaolan, Zheng, Hua, Wu, Sha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353443/
https://www.ncbi.nlm.nih.gov/pubmed/34386017
http://dx.doi.org/10.3389/fimmu.2021.725330
Descripción
Sumario:Gynecologic malignancies, mainly including ovarian cancer, cervical cancer and endometrial cancer, are leading causes of death among women worldwide with high incidence and mortality rate. Recently, adoptive T cell therapy (ACT) using engineered T cells redirected by genes which encode for tumor-specific T cell receptors (TCRs) or chimeric antigen receptors (CARs) has demonstrated a delightful potency in B cell lymphoma treatment. Researches impelling ACT to be applied in treating solid tumors like gynecologic tumors are ongoing. This review summarizes the preclinical research and clinical application of engineered T cells therapy for gynecologic cancer in order to arouse new thoughts for remedies of this disease.

Ejemplares similares